Biotechnology
KdT Ventures Launches New Biotech Startup to Develop NGM Bio’s Rare Disease Drug Candidate NGM313
KdT Ventures, NGM Bio, NGM313, Rare Disease, Biotechnology, Drug Development, Phase 2 Trial
Aurion Biotech Advances to Phase III Trials with Promising Allogeneic Cell Therapy for Corneal Oedema
Allogeneic cell therapy, Corneal oedema, Corneal endothelial dysfunction, AURN001, Phase III clinical trials, Vision restoration, Biotechnology, Clinical development
Biopharma’s New Horizon: Industry Leaders Converge at JPM 2025
JPM 2025, Biopharma, Jennifer Doudna, Janet Woodcock, Robert Nelsen, Scott Gottlieb, Healthcare, Gene Editing, CRISPR, Pharmaceutical Industry, Biotechnology
Candid Therapeutics Expands T-Cell Engager Pipeline with Strategic Collaborations
T-cell engagers, autoimmune diseases, biotechnology, Candid Therapeutics, collaborations, EpimAb Biotherapeutics, Nona Biosciences
Candid Therapeutics Expands T-Cell Engager Portfolio with Three New R&D Collaborations
Candid Therapeutics, T-cell engagers (TCEs), autoimmune diseases, R&D collaborations, biotechnology partnerships
Gilead Sciences Appoints Dietmar Berger as Chief Medical Officer to Spearhead R&D Revamp
Gilead Sciences, Dietmar Berger, Chief Medical Officer, R&D Reset, Biotechnology, Pharmaceutical Industry
Negev Labs Unveils Next-Gen Psychedelic Therapies with Non-Hallucinogenic Neuroplastogens
Negev Labs, neuroplastogens, psychedelic therapies, non-hallucinogenic psychedelics, mental health treatments, biotechnology company builder
nChroma Bio Emerges from Chroma Medicine and Nvelop Therapeutics Merger, Secures $75 Million to Advance Genetic Medicines
nChroma Bio, Chroma Medicine, Nvelop Therapeutics, Genetic Medicines, Epigenetic Editing, Non-Viral Delivery, Biotechnology, Merger, Financing
BIOSECURE Act Excluded from US Defense Bill, Offering Reprieve to Chinese Biotechs
BIOSECURE Act, Chinese biotechs, US defense bill, biotechnology supply chains, national security concerns
Novo Nordisk Invests $409M in New Quality Control Lab in Denmark
Novo Nordisk, quality control lab, Denmark, pharmaceutical investment, biotechnology